Your browser doesn't support javascript.
loading
The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.
Harper, Diane M; Nieminen, Pekka; Donders, Gilbert; Einstein, Mark H; Garcia, Francisco; Huh, Warner K; Stoler, Mark H; Glavini, Katerina; Attley, Gemma; Limacher, Jean-Marc; Bastien, Berangere; Calleja, Elizabeth.
  • Harper DM; Department of Family and Community Medicine, Obstetrics and Gynecology, University of Missouri Kansas City, 7900 Lee's Summit Road, Kansas City, MO 64139, USA. Electronic address: harperdi@med.umich.edu.
  • Nieminen P; Department of Obstetrics and Gynaecology, Helsinki University Hospital and Helsinki University, Box 615, 00029 HUS, Helsinki, Finland. Electronic address: pekka.nieminen@hus.fi.
  • Donders G; Department of Obstetrics and Gynaecology, University Hospital Antwerp, Wilrijksesteenweg 10, 2000 Antwerp-Ekeren, Belgium. Electronic address: Gilbert.Donders@uza.be.
  • Einstein MH; Department of Obstetrics and Gynecology, Albert Einstein Cancer Center and Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA. Electronic address: me399@njms.rutgers.edu.
  • Garcia F; Center of Excellence in Women's Health at the University of Arizona, 1501 N Campbell Ave, Tucson, AZ 85714, USA. Electronic address: Francisco.Garcia@pima.gov.
  • Huh WK; Department of Obstetrics and Gynecology, University of Alabama, 1700 6th Avenue South, WIC Room 10250, Birmingham, AL 35233, USA. Electronic address: whuh@uabmc.edu.
  • Stoler MH; Surgical Pathology, P.O. Box 800214, Department of Pathology, University of Virginia Health System, University of Virginia, Charlottesville, VA, USA. Electronic address: mhs2e@me.comall.
  • Glavini K; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Building 93, Room 7.38.01, Grenzacherstrasse 124, Basel 4070, Switzerland. Electronic address: katerina.glavini@roche.com.
  • Attley G; Roche Pharmaceutical Research & Early Development, Roche Innovation Center New York, 430 E. 29th Street New York City, New York 10016, USA. Electronic address: gemma.attley.ga1@roche.com.
  • Limacher JM; Department of Medical Affairs, Transgene SA, 400 Bb Gonthier d'Andernach Parc d'innovation, CS80166, 67405 Illkirch-Graffenstaden Cedex, France. Electronic address: jean-marc.limacher@ch-colmar.fr.
  • Bastien B; Department of Biostatistics, Transgene S.A., Boulevard Gonthier d'Andernach Parc d'innovation, CS80166, 67405 Illkirch-Graffenstaden Cedex, France. Electronic address: bastien@transgene.fr.
  • Calleja E; Roche Pharmaceutical Research & Early Development, Roche Innovation Center New York, 430 E. 29th Street New York City, New York 10016, USA. Electronic address: elizabethcalleja@netscape.net.
Gynecol Oncol ; 153(3): 521-529, 2019 06.
Article en En | MEDLINE | ID: mdl-30955915
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Displasia del Cuello del Útero / Neoplasias del Cuello Uterino / Infecciones por Papillomavirus / Vacunas contra Papillomavirus Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Middle aged Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Displasia del Cuello del Útero / Neoplasias del Cuello Uterino / Infecciones por Papillomavirus / Vacunas contra Papillomavirus Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Middle aged Idioma: En Año: 2019 Tipo del documento: Article